DOJ Announces 2026 National Health Care Fraud Takedown: 455 Defendants Charged in Alleged $6.5 Billion Fraud Schemes

On June 23, 2026, the Department of Justice (DOJ) announced its “2026 National Health Care Fraud Takedown,” a nationwide enforcement action resulting in charges against 455 defendants, including 90 doctors and other licensed medical professionals. According to DOJ, the cases involve more than $6.5 billion in alleged false claims, as well as alleged patient harm, opioid diversion, kickbacks, medically unnecessary services, and large-scale efforts to exploit federal health care programs.

The DOJ’s press release emphasizes coordinated criminal, civil, and administrative enforcement, expanded use of data analytics, closer cooperation between federal and state agencies, and a willingness to pursue not only individual providers, but also executives, marketers, owners, and corporate actors connected to alleged fraud schemes.

According to DOJ, the takedown involved cases in 56 federal districts and 45 states and territories, with participation from 50 Medicaid Fraud Control Units. DOJ also announced related CMS actions suspending 1,079 providers and revoking billing privileges for 1,403 providers, along with HHS-OIG exclusions, civil monetary penalty actions, civil settlements, and DEA administrative actions seeking revocation of controlled-substance authority.

Wound Care and Allografts

One of the major areas highlighted in the takedown was wound care, particularly alleged schemes involving amniotic wound allografts. The DOJ announced charges against 11 defendants, including medical professionals and a company executive, across six federal districts. The government alleges that certain providers billed Medicare billions of dollars for allografts and that the spike in billing was driven by kickbacks and medically unnecessary applications rather than legitimate patient need.

The DOJ’s description of these cases is notable because it ties together several themes that have become increasingly common in healthcare fraud enforcement: rapid growth in utilization, high reimbursement, aggressive marketing, medically vulnerable patients, lack of coordination with treating physicians, and alleged kickback arrangements that create financial incentives for unnecessary care.

For compliant providers, this is an important reminder that billing data does not exist in a vacuum. Unusual increases in utilization, high-cost services, atypical patterns compared to peers, or sudden revenue growth in a particular service line may draw scrutiny even before a complaint, whistleblower, or patient report. The DOJ specifically credited data analytics with detecting a spike in allograft payments, which then led to prosecution.

The Government Is Leaning Hard Into Data Analytics

Perhaps the most significant aspect of the DOJ’s announcement is its emphasis on data analytics. The DOJ stated that its Health Care Fraud Unit’s Data Fusion Center used advanced analytics in many of the cases announced. The DOJ also highlighted the first prosecution arising from its Financial Intelligence Review Team, which combines claims analytics with financial analysis. In that case, the DOJ alleged that a Medicaid provider billed for hundreds of hours of counseling and therapy services per day—more than staff could realistically provide—and that data showed patients were hospitalized elsewhere on days services were billed.

The DOJ also announced that the Fraud Division and CMS entered into an agreement to allow the DOJ to use cloud computing space in the CMS Integrated Data Repository environment to deploy advanced analytics algorithms and artificial intelligence (AI) tools. The DOJ also referenced agreements with DHS and the FTC aimed at breaking down data silos and improving access to information relevant to healthcare fraud investigations.

Medicaid Fraud Remains a Major Priority

The DOJ also described this year’s takedown as including the largest number of Medicaid fraud defendants and Medicaid fraud loss charged in Department history. According to the announcement, 295 defendants were charged in connection with more than $518 million in alleged false claims submitted to Medicaid.

The Medicaid cases described by DOJ included alleged schemes involving social adult day care services, behavioral health, crisis stabilization services, and substance-abuse-related services. Several of the alleged schemes involved vulnerable patient populations, including homeless individuals, individuals struggling with substance abuse, and Medicaid beneficiaries whose identifying information was allegedly used to bill for services that were not medically necessary or not provided.

This focus is consistent with broader enforcement trends. Medicaid-funded behavioral health, substance abuse treatment, personal care services, adult day care, and related service lines continue to receive close attention from federal and state enforcement authorities. Providers in these areas should expect scrutiny of medical necessity, patient eligibility, referral sources, documentation, staffing capacity, and whether services were actually rendered as billed.

Controlled Substances and DEA Exposure

The takedown also included charges against 36 defendants, including 28 licensed medical professionals, in connection with alleged illegal opioid distribution and controlled-substance diversion. The DOJ described cases involving Schedule II refills allegedly issued without appropriate patient interaction and a separate alleged conspiracy involving the distribution of millions of opioid and other controlled-substance pills.

For physicians, pharmacists, clinics, and other providers that prescribe or dispense controlled substances, the enforcement risk is not limited to criminal prosecution. The DOJ also reported 928 DEA administrative cases seeking revocation of authority to handle or prescribe controlled substances since October 1, 2025.

Compliance Takeaways for Healthcare Providers

While the DOJ announcement is not cause for panic, it is certainly cause for healthcare providers to reassess whether their compliance programs are capable of identifying the same types of issues the government is now looking for.

Healthcare providers should pay particular attention to service lines with rapid growth, high reimbursement, heavy use of marketers, unusual referral patterns, large increases in utilization, services provided to vulnerable patient populations, or billing patterns that appear inconsistent with staffing, time, geography, or patient acuity. Providers should also evaluate whether their documentation actually supports the services billed and whether compensation, marketing, and referral arrangements have been reviewed for Anti-Kickback Statute and Stark Law risk.

GWB represents healthcare providers in connection with government investigations and False Claims Act litigation. If you need assistance with such a matter, contact us today.